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Abstract
Background: The exhaustive collection of new sarcoma cases and their second histologic review offer a unique
opportunity to study their incidence and time trends in France according to the major subtypes.
Methods: Data were collected from population-based cancer registries covering 22% of the French population.
Crude and world age-standardized incidence rates (ASR) were estimated according to anatomic, histological and
genetic groups, age and sex over the 2010–2013 period.
Results: Time trends in incidence were calculated by the annual percent change over the 2000–2013 period.
During the most recent period (2010–2013), 3942 patients with sarcoma were included. The ASR of soft-tissue
and bone sarcomas, and gastro-intestinal stromal tumors (GIST) were 2.1, 1.0 and 0.6, respectively. For the
four most frequent histological subtypes (unclassified, leiomyosarcoma, GIST and liposarcoma), the ASR ranged
from 0.4 to 0.7. ASRs were 1.9 for complex genomic and 1.3 for recurrent translocation sarcomas. The time-
trend analysis showed a significant increase of sarcoma incidence rate between 2000 and 2005, which
stabilized thereafter. Incidence rates increased for four histological subtypes (GIST, chondrosarcoma,
myxofibrosarcoma, solitary fibrous tumors) and decreased for three (leiomyosarcomas, Kaposi sarcoma and
fibrosarcoma).
Conclusion: To our knowledge, this study is the first to investigate sarcoma incidence based on a systematic
pathological review of these cancers and on the updated sarcoma classifications. Due to the paucity of
literature on sarcomas, future studies using data from population-based cancer registries should consider a
standardized inclusion criterion presented in our study to better describe and compare data between
countries.
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Background
Sarcomas are a heterogeneous group of rare malignant
tumors derived from primitive mesenchymal cells. These
tumors arise from muscle, connective tissue, supportive
tissue and vascular tissue, and more than 80 histologic
subtypes are included in the 2013 World Health
Organization (WHO) Classification of Tumors of Soft
Tissue and Bone [1]. In addition to having a multiple
and complex histology, these tumors can occur in al-
most any anatomic site. In spite of these facts, sarcomas
account for less than 1% of all adult cancers and for
about 20% of all malignant solid tumors in children, ad-
olescents and young adults [2].
From an epidemiological point of view, the lack of a
unified method of reporting sarcomas has led to consid-
erable variations in the reported incidence and time
trends Sarcomas are sometimes mistaken for carcinomas
of the same organ, and can involve a variety of localiza-
tions. As a consequence, 30 % of sarcomas are misclassi-
fied at initial diagnosis [3]. In addition, sarcomas
encompass a wide variety of histological and molecular
subtypes and are categorized in rapidly evolving pheno-
typic and molecular subgroup classification schemas
now used for sarcoma diagnosis, which has a growing
impact on the management of patients [4]. Furthermore,
innovation in immune-histochemistry and molecular
biology techniques in the last three decades has led to
major changes in the diagnosis and classification of sar-
coma subtypes.
Currently, data for sarcomas in the French population
are provided by the reference networks for sarcomas that
collect and manage cases of soft tissue, bone and visceral
sarcomas. Reference networks propose a systematic sec-
ond histologic review by expert pathologists [5–7]. A few
French studies carried out by these reference networks
provided world age-standardized incidence rates of 4.8
and 3.3 per 100,000 inhabitants per year for all sarcomas
and soft-tissue sarcomas (STS) respectively [8, 9]. How-
ever, data from these reference networks based on the vol-
untary participation are not totally exhaustive.
Besides reference networks, cancer surveillance informa-
tion is coming from the French Network of population-
based cancer registries that exhaustively collects all newly
diagnosed and confirmed cancer cases within geographical
areas in France [10]. The exhaustive collection of sarcoma
cases from population-based cancer registries and the sys-
tematic second review of diagnosis from reference centers
offer an optimal framework to study the incidence and
time trends of sarcomas in France. The incidence trends
have never been studied in France and the results from
other countries are divergent [11]. We undertook this
study to describe sarcoma entity according to anatomic
sites, histologic subtypes and genetic groups based on
guidelines developed by sarcoma specialists.
Methods
Data sources
Cases included in this study were children and adults
with sarcoma diagnosed between January 1, 2000 and
December 31, 2013, and living in one of the administra-
tive areas covered by a population-based cancer registry
of the French Network (details in online supplementary
material). The French sarcoma pathological reference
network (RRePS) and the French reference Network for
bone sarcoma and rare bone tumors (RESOS) propose a
systematic second histologic review and confirmation for
all diagnoses of sarcomas across France [6].
Data collection and classification
The following data were collected for each case: general
demographic characteristics of the patients (age, sex, and
residence area), the date of diagnosis, the anatomical
site, and the histology of the tumor according to the
International Classification of Diseases for Oncology,
third edition (ICD-O-3) (12).
This study included intermediate (only with a “/3” be-
havior) and malignant sarcomas presenting morphologic
criteria described in the 2013 WHO Classification of Tu-
mors of Soft Tissue and Bone (fourth edition), regardless
of the anatomic site [1]. This recent classification in-
cludes histologic updates not defined in ICD-O-3 and
new terms, synonyms, morphology and behavior codes.
For this reason, and whenever possible, cases were re-
classified according to the updated version. The align-
ments from ICD-O-3 to the 2013 WHO standard
classification of tumors have been validated by a panel of
sarcoma specialists (clinical and pathological experts)
from sarcoma Networks (NP, JMC and IRC).
Certain alignments could not be performed: ten mor-
phological terms not described in this updated classifica-
tion (e.g. sarcoma NOS, periosteal fibrosarcoma, fascial
fibrosarcoma …) have been maintained for analyses.
Conversely, well differentiated liposarcoma and chon-
droblastoma have been changed from malignant to bor-
derline diseases. In the same way, behaviors for
dermatofibrosarcoma protuberans and pigmented der-
matofibrosarcoma protuberans have been also changed
from malignant to borderline with henceforth, only
fibrosarcomatous dermatofibrosarcoma protuberans
which is coded as malignant behavior. In our analyses,
we have made the choice to keep all dermatofibrosarco-
mas. Indeed, we do not have the possibility to differenti-
ate if this is a dermatofibrosarcoma borderline or
malignant. Besides, endometrial stromal sarcoma NOS
(89303), low grade endometrial stromal sarcoma (89313)
and stromal sarcoma (89353) not described in the WHO
2013 have been also included. Additional details on the
list and choice of classification systems are provided in
the online supporting material (see Additional File 1).
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This classification also provides new genetic and
molecular data for each histologic entity allowing a
better characterization of sarcomas. The same group
of experts were consulted with the aim of proposing
the optimal classification system for sarcomas based
on the genetic profile. Two main distinct genetic
groups were defined: (i) sarcomas defined with simple
genetics based on recurrent translocations (e.g. Ewing
sarcoma, myxoïd liposarcoma), activating or inactivat-
ing mutations (e.g epithelioid sarcoma, gastrointestinal
stromal tumor), MDM2 amplification (e.g. dedifferen-
tiated liposarcoma, low-grade central osteosarcoma);
and (ii) sarcomas with complex genomic profiles (e.g.
angiosarcoma, leiomyosarcoma). Another group was
defined for miscellaneous and undefined alterations.
The list of histology codes according to their genetic
groups is presented in the supplementary material.
This study is based on data from cancer registries
gathered in the French network of cancer registries and
a representative of each registry was involved in the
study and approved the use of its data All French regis-
tries received an authorization to collect patient data
from the data protection authority (Commission Natio-
nale de l’Informatique et des Libertés). Ethics approval
and consent to participate were not required for this
study which is an observational research without direct
contact with patient.
Statistical analyses
Two datasets were used: i) the first one was used to esti-
mate the incidence of patients diagnosed during the
2010–13 period and that included data from 19 regis-
tries; and ii) the second one was used to examine trends
in the incidence from 2000 to 2013 in only 11 registries
for which data were available over the entire studied
period. Incidence rates were presented per 100,000
person-years.
The incidence of sarcomas was described according to
1) the anatomic group (i.e. soft-tissue, bone, gastro-
intestinal, skin, female genital organs, other viscera and
other sites), and to 2) histologic and 3) genetic groups
based on guidelines developed by sarcoma specialists
(see Additional File 1).
Age-standardized incidence rates (ASR) were esti-
mated using direct standardization and were calculated
using the population data for each age group and year
supplied by the National Institute of Statistics and Eco-
nomic Studies (www.insee.fr) and the European (ASR-E),
Segi World (ASR-W), and the US (ASR-US) standard
populations. The analyses presented here describe the
overall ASR and the ASR by sex. Age-specific incidence
rates are provided by age groups (0–14; 15–24; 25–39;
40–64; 65–74 and 75 and more) and by sex and pre-
sented in figures.
Time trends were calculated using Joinpoint Trend
Analysis Software setting a maximum of a single Join-
point (details in online supplementary material). The an-
nual percent change (APC) with the 95% confidence
interval (CI) was estimated according to topographic
and histologic groups.
Results
Over the 2010–13 period, sarcomas accounted for 1.3%
(3942/307,862) of all malignant tumors diagnosed over
the French registry area. The male/female ratio for over-
all sarcomas was 1.0 but ranged from 0.5 for angiosarco-
mas to 6.2 for Kaposi sarcomas (KS) (Table 1). The
median age was 63 years (range: 0–106) with large inter-
group variations. About 9% of subjects were under 24
years and 27% were older than 75 years. Almost half of
the cases were soft tissue sarcomas (45%). The most
frequent histological subtypes were undifferentiated or
unclassified sarcomas (16%), leiomyosarcoma (14%) and
GIST (13%). Sarcomas with complex genomics
accounted for the most frequent molecular profile (40%).
The crude incidence rate and ASR-W of sarcomas
were 7.4 and 5.0, respectively (Table 2). The ASR-W of
soft tissue, bone and gastro-intestinal sarcomas were 2.1,
1.0 and 0.6, respectively. For the five most frequent
histological subtypes, the ASR-W ranged from 0.3 to 0.7
with gender variations. For the two most frequent gen-
omic profiles (over 60% of all sarcoma cases) the ASR-
W was 1.9 for complex genomic and 1.3 for recurrent
translocation events.
The overall sarcoma incidence peaked at 22 in patients
aged 75 or over (data not shown). Age-specific rates for
soft tissue, viscera and skin sarcomas were relatively
stable among patients aged between 0 and 40 years, and
then increased with age (Fig. 1). This increase was less
pronounced in women. In men, bone sarcomas pre-
sented a biphasic profile with a first peak in young
people between 15 and 25 years of age and a second
peak in adults aged between 65 and 74 years of age.
With respect to histological subtypes, age-specific inci-
dence rates had various profiles (see Additional File 2).
According to the genomic profile, the incidence in-
creased steadily with age, except for tumors harboring
recurrent translocations and MDM2 amplification
among women (see Additional File 3).
The ASR-W for all sarcomas increased between
2000 and 2005 (APC = 3.6%), and remained stable
since 2005 (non-significant APC, Table 3). According
to the anatomic site, the ASR-W decreased for skin
sarcomas (APC = -2.0%) and female genital tumors be-
tween 2005 and 2013 (APC = -2.2%). Stratifying by
major histological subtypes, the ASR-W increased for
GIST (APC = 3.7%), chondrosarcoma (APC = 4.1%),
myxofibrosarcoma (8.2%) and solitary fibrous tumors
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Table 1 Gender distribution of sarcoma patients according to age and topographic, genomic and histologic groups. FRANCIM
network data 2010–2013 (19 registries)
Male Female Overall Sex
ratio
M/F
n % n % n %
Age group (in years)
0–14 81 4.1 81 4.1 162 4.1 1.0
15–24 99 5.0 79 4.0 178 4.5 1.3
25–39 197 10.0 160 8.1 357 9.1 1.2
40–64 671 34.1 738 37.4 1409 35.7 0.9
65–74 376 19.1 379 19.2 755 19.2 1.0
75 and more 546 27.7 535 27.1 1081 27.4 1.0
Sarcoma topographic groups
Soft tissue 972 49.3 812 41.2 1784 45.3 1.2
Bone 310 15.7 259 13.1 569 14.4 1.2
Skin 262 13.3 167 8.5 429 10.9 1.6
Viscera
Gastro-intestinal organs 291 14.8 287 14.6 578 14.7 1.0
Female genital organs – – 282 14.3 282 7.2 –
Others visceral organs 102 5.2 129 6.5 231 5.9 0.8
Other anatomic sites 33 1.7 36 1.8 69 1.8 0.9
Sarcoma genomic groups
Complex genomic alterations 723 36.6 847 43.0 1570 39.8 0.9
MDM2 amplification 135 6.9 81 4.1 216 5.5 1.7
Mutations 274 13.9 276 14.0 550 14.0 1.0
Recurrent translocations 340 17.3 438 22.2 778 19.7 0.8
Undefined/Miscellaneous alterations 498 25.3 330 16.7 828 21.0 1.5
Sarcoma histologic groups
Unclassified sarcomaa 327 16.6 308 15.6 635 16.1 1.1
Leiomyosarcoma 205 10.4 346 17.5 551 14.0 0.6
GIST 246 12.5 250 12.7 496 12.6 1.0
Liposarcoma 228 11.6 130 6.6 358 9.1 1.8
Dedifferentiated liposarcoma 125 6.3 69 3.5 194 4.9 1.8
Round cell \ Myxoid liposarcoma 42 2.1 29 1.5 71 1.8 1.4
Pleomorphic liposarcoma 18 0.9 7 0.4 25 0.6 2.6
Liposarcoma NOS 43 2.2 25 1.3 68 1.7 1.7
Chondrosarcoma 123 6.2 118 6.0 241 6.1 1.0
Dermatofibrosarcoma 101 5.1 124 6.3 225 5.7 0.8
Kaposi sarcoma 156 7.9 25 1.3 181 4.6 6.2
Angiosarcoma 54 2.7 115 5.8 169 4.3 0.5
Osteosarcoma 84 4.3 71 3.6 155 3.9 1.2
Ewing sarcoma 72 3.7 65 3.3 137 3.5 1.1
Myxofibrosarcoma 75 3.8 49 2.5 124 3.1 1.5
Rhabdomyosarcoma 66 3.4 51 2.6 117 3.0 1.3
Embryonal rhabdomyosarcoma 27 1.4 16 0.8 43 1.1 1.7
Alveolar rhabdomyosarcoma 10 0.5 12 0.6 22 0.6 0.8
Pleomorphic rhabdomyosarcoma 14 0.7 7 0.4 21 0.5 2.0
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(12.2%) and decreased for leiomyosarcoma (APC = -
2.6%), Kaposi sarcoma (− 4.1%) and fibrosarcoma
(APC = -9.2%). All trend figures are provided in the
online supplementary material (see Additional Files 4
and 5).
Discussion
In this study, we precisely described the incidence of sar-
comas according to different classifications (anatomic,
histologic and genetic) using data from population-based
cancer registries. To our knowledge, this is one of the
first reports on sarcomas based on a systematic patho-
logical review of these cancers while taking into account
the updated sarcoma classifications.
In this study, sarcomas accounted for 1.3% of all ma-
lignant tumors (1.1% for soft tissue -including skin and
viscera- and 0.2% for bone) and had an ASR-E of 6.1 per
100,000 person-years over the 2010–2013 period
(European population standard). The ASR-E was slightly
higher than that reported in Europe [12]. Data compari-
son between countries is difficult due to the heterogen-
eity of sarcoma definition used as inclusion criteria. This
heterogeneity is mainly related to some analysis charac-
teristics: i) certain specific histological subtypes are not
consistently included in analyses (e.g. Kaposi sarcoma or
dermatofibroma sarcoma); ii) some studies consider
adults and children separately, while others mix them;
and iii) anatomic sites may be limited to specific sites
such as STS. The current approach to describe sarcomas
using registry data based on expert recommendations
are expected to better follow epidemiological indicators
and to carry out reliable comparisons between countries.
With respect to the anatomic site, ASR-E for STS
(2.7) in our study was below most published inter-
national incidence rates. This may be explained by
the exclusion of visceral sarcomas of soft tissue and
the different description of well-differentiated liposar-
coma compared to the WHO 2013 classification. In
the current study, ASR-Ws for bone sarcomas among
males and females (1.1 and 0.9 respectively) were
close to those recently reported in five continents
(2010–13 period, ASR-W 0.8–1.2 in males and 0.5–
1.0 in females) [13]. For visceral sarcomas, the com-
parison between studies with inclusion periods close
to that in the present study showed ASR-E similar to
ours [8, 14]. In contrast, the ASR was greater than
that reported in the RARECARE project, which may
be due to differences in the definition of visceral sar-
comas (GIST not included) [14].
The comparison of ASRs for main histologic groups
between studies with a shorter inclusion period showed
that the ASR-E for leiomyosarcoma (0.8; 0.6 for males
and 1.0 for females) was greater than that reported in
France (0.6) and was similar to that reported in three
European regions (0.5 for males and 1.0 for females) [8,
14]. ASR-E for liposarcoma in our study (0.5; 0.7 for
males and 0.4 for females), was lower than that reported
in France (0.8) and in three European regions (1.06 for
Table 1 Gender distribution of sarcoma patients according to age and topographic, genomic and histologic groups. FRANCIM
network data 2010–2013 (19 registries) (Continued)
Male Female Overall Sex
ratio
M/F
n % n % n %
Spindle cell rhabdomyosarcoma 7 0.4 7 0.4 14 0.4 1.0
Rhabdomyosarcoma NOS 8 0.4 9 0.5 17 0.4 0.9
Nerve Sheath Tumors 38 1.9 44 2.2 82 2.1 0.9
Endometrial stromal sarcoma – – 81 4.1 81 2.1 –
Synovial sarcoma 37 1.9 40 2.0 77 2.0 0.9
Spindle cell synovial sarcoma 19 1.0 20 1.0 39 1.0 1.0
Biphasic synovial sarcoma 3 0.1 7 0.3 10 0.2 0.4
Synovial sarcoma NOS 15 0.8 13 0.7 28 0.7 1.2
Chordoma 40 2.0 27 1.4 67 1.7 1.5
Solitary fibrous tumor, malignant 33 1.7 33 1.7 66 1.7 1.0
Fibrosarcoma 15 0.8 16 0.8 31 0.8 0.9
Malignant myoepithelioma 12 0.6 11 0.6 23 0.6 1.1
Epithelioid haemangioendothelioma 9 0.5 11 0.6 20 0.5 0.8
Other (with fewer than 20 cases) 49 2.5 57 2.9 106 2.7 0.7
Overall 1970 100.0 1972 100.0 3942 100.0 1.0
aUnclassified sarcomas include: Sarcoma NOS (ICDO-88003), undifferentiated spindle cell sarcoma (ICDO-88013), undifferentiated pleomorphic sarcoma (ICDO-
88023), undifferentiated round cell sarcoma (ICDO-88033), epithelioid sarcoma (ICDO-88043), undifferentiated sarcoma NOS (ICDO-88053)
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males and 0.59 for females), which may be attributed
to differences in the definition of liposarcoma as in-
clusion criteria [8, 14]. In our study, we found an
ASR-W for osteosarcoma slightly lower than that of
chondrosarcoma (0.28 versus 0.34). For male, ASR-W
was equivalent (0.34 versus 0.32). A recent
population-based study from Swiss cancer registries
showed similar results [15]. In contrast, others studies
based on older inclusion period of sarcoma diagnosis
found an ASR-W slightly higher for osteosarcoma [8,
16]. However, looking at the trend in our study (Add-
itional File 5), we can notice that the ASR-W of
osteosarcoma was actually higher over the period
2000–2005 than the ASR-W of chondrosarcoma in
accordance with these studies. The increasing trend
in the ASR of chondrosarcoma and the stabilization
of the ASR of osteosarcomas may logically explain
why the incidence of chondrosarcomas has been
higher than that of osteosarcomas in recent years.
Molecular biology of sarcomas, available for diagnosis
in France since 2010 is a complementary approach and
has led to a molecular classification for sarcomas [17].
For the first time, we provided ASR at national level and
showed molecular profiles by age groups.
This study provides the first time trend analysis of sarco-
mas in France and shows that ASR-W for sarcomas in-
creased between 2000 and 2005 (APC= 3.6%) and
stabilized from 2005. The current study has not shown an
increase in ASR-W for soft-tissue sarcomas. This is in con-
trast to reports in others countries covering different pe-
riods: in the United States APC was 1.2% for males and
0.8% for females between 1978 and 2001, in Japan APC was
0.6% between 1978 and 2007 and in Serbia APC was 0.77%
between 1985 and 2009 [18–20]. We report a significant
decrease in incidence for skin sarcomas over the study
period and for female genital sarcomas since 2005. Some
histological subtypes have shown a significant decrease over
the study period: leiomyosarcoma, KS and fibrosarcoma.
The decline for KS has also been described in the popula-
tion from the United States over the same period [21].
These changes are consistent with the improvement in ac-
cess for antiretroviral therapy among HIV-infected patients
and the declining AIDS incidence in developed countries.
The decrease in incidence of leiomyosarcoma and
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Fig. 1 Age-specific incidence rates of sarcomas per 100,000 person-years according to topographic groups. FRANCIM network data 2010–2013
(19 registries)
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fibrosarcoma could be explained by a histological classifica-
tion published by the WHO in 2002 that includes new data
of immunohistochemistry and new histological subtypes.
Similarly, we report an increase in incidence of GIST, likely
related to the introduction in the early 2000s of an immu-
nohistochemical diagnostic test specific to GIST tumors
(KIT-activating mutations). Further, the increase in GIST
was more noticeable before 2005 and stabilised after 2005.
The time trend analysis also revealed a significant increase
for chondrogenic sarcomas (APC= 4.4%). Such increase
has been reported in a study from the United States includ-
ing only women (1976–2005) [20], whereas a study from
the United Kingdom showed the same trend in incidence
for both sexes (1988–2007) [13]. The strongest hypothesis
to explain the increased risk of chondrogenic sarcoma in
women is the introduction of exogenous estrogen
Table 3 Annual percentage change of world age-standardized incidence rate by topographic groups, histologic types. FRANCIM
network data 2000–2013 (11 registries)
n Joinpoint APC 95% CI
Sarcomas by topographic groups
Soft Tissue 3766 0.8 (−0.4; 2.0)
Bone 1193 1.2 (−0.4; 2.9)
Skin 1062 -2.0a (−3.5; −0.4)
Viscera tumors organs
Gastro-intestinal organs 1053 1.5 (−0.3; 3.3)
Female genital organs 297 2000–2005 4.2 (−4.2; 13.2)
376 2005–2013 −6.7a (−10.4; −2.7)
Other visceral organs 540 −1.7 (−5.1; 1.8)
Other anatomic sites 171 1.0 (−3.4; 5.6)
Sarcomas by histologic groups
Unclassified sarcoma 1513 −1.6 (−3.6; 0.3)
Leiomyosarcoma 1281 −2.6a (−4.6; −0.6)
GIST 822 3.7a (0.8; 6.8)
Liposarcoma 713 1.3 (−1.1; 3.7)
Dermatofibrosarcoma 496 0.6 (−1.4; 2.7)
Chondrosarcoma 454 4.1a (1.6; 6.6)
Kaposi sarcoma 419 −4.1a (−6.8; −1.4)
Osteosarcoma 359 −0.6 (−3.7; 2.6)
Angiosarcoma 335 2.2 (−1.2; 5.7)
Ewing sarcoma 330 −0.2 (−4.1; 3.8)
Rhabdomyosarcoma 286 −1.1 (−6.2; 4.4)
Others (with fewer than 20 cases) 226 4.1 (−1.3; 9.8)
Synovial sarcoma 219 1.2 (−4.2; 6.9)
Nerve Sheath Tumors 191 −0.1 (−4.3; 4.4)
Myxofibrosarcoma 183 8.2a (0.4; 16.6)
Endometrial stromal sarcoma 173 −3.7 (−7.4; 0.1)
Fibrosarcoma 151 −9.2a (−15.7; −2.3)
Chordoma 126 0.8 (−4.8; 6.6)
Solitary fibrous tumor. Malignant 102 12.2a (6.2; 18.5)
Epithelioid haemangioendothelioma 55 – –
Myoepithelial carcinoma 24 – –
Total 3359 2000–2005 3.6a (0.2; 7.1)
5099 2005–2013 −1.4 (−2.9; 0.1)
Note. Joinpoint = years when statistically significant changes in incidence trend occurred
APC Annual Percent Change, CI Confidence Interval
aIndicates that the APC is significantly different from 0 at the alpha = 0.05 level
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exposures (oral contraceptives, hormone therapy), whereas
other factors has to be identified in men [13, 16].
The different incidence trends for sarcomas reported
over the world may partly be explained by variations in
diagnosis practices and the classification used. The im-
pact of environmental factors in the etiology of these
cancers may also be a point at issue. However, the large
heterogeneity of histological subtypes and the rarity of
sarcomas prevent examining this association and draw-
ing conclusions from existing environmental epidemio-
logical studies. A national French study on the etiology
of sarcomas (Etiosarc) has been launched to study the
possible effect of environmental factors [22].
A major strength in this study is that the incidence of
sarcomas was estimated using the 2013 WHO classifica-
tion [1]. Whenever possible, registry data was converted
to the latest classification to take into account changes
and evolutions between different classifications (e.g. new
morphological terms, obsolete morphological codes and
terms).
Moreover, this study is the first to describe sarcomas in a
geographic area where an expert sarcoma pathologist re-
views the pathologic diagnosis. Contrary to imperfectly esti-
mated sarcoma incidence rates, this review allows to
provide a consistent incidence of sarcomas. A French study,
confirmed these results and indicated that 45% of sarcomas
are misclassified at initial diagnosis and that 19% have
complete discordance [3]. For this reason, the review for
sarcoma diagnosis is necessary to estimate a consistent inci-
dence and more so for the different subgroups. In France,
the second review was based on voluntary participation be-
fore the year 2010. Thereby, we cannot be certain that the
review was obtained for all sarcomas in the period 2000–
2010, even if significant efforts were made by French sar-
coma network in order that pathologists systematically send
slides of any newly diagnosed of sarcomas. For this reason,
the estimated incidence over the 2010–2013 seems to be
most relevant and reliable.
Conclusion
This study provided the opportunity to precisely de-
scribe the incidence of sarcomas according to three dif-
ferent groups (anatomic, histologic and genetic) defined
by sarcoma specialists using data from population-based
cancer registries. To our knowledge, this study is the
first to report sarcoma incidence based on a systematic
pathological review of these cancers and taking into ac-
count the updated sarcoma classifications. Due to litera-
ture paucity on sarcomas, future studies using data from
population-based cancer registries will have to consider
a strict inclusion criterion presented in our study to bet-
ter describe and compare data between countries. The
molecular classification will be useful for etiological
studies as incidence studies.
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